SCHEMBL5223317

SCHEMBL5223317

COc1ccc(CC(O)CN2C[CH]N(c3ccc4[nH]ncc4c3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.47
CYP2D6 P10635 2/20 0.46
ROCK2 O75116 7/20 0.43
ROCK1 Q13464 3/20 0.43
CCR2 P41597 1/20 0.43
CYP3A4 P08684 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
PRKG1 Q13976 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
ABCB1 P08183 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6207329 0.80 KCNH2 (0.49) KCNH2CYP2D6CYP3A4MEN1KMT2A
SCHEMBL4490875 0.76 ROCK2 (0.55) CYP2D6ROCK2ROCK1CCR2MEN1
SCHEMBL6205691 0.74 KCNH2 (0.51) KCNH2CYP3A4PRMT5WDR77
SCHEMBL5226887 0.73 KCNH2 (0.50) KCNH2CYP3A4PRMT5WDR77
SCHEMBL7705235 0.73 CYP2D6 (0.54) CYP2D6MEN1KMT2AABCB1
SCHEMBL6256736 0.68 CYP2D6 (0.55) CYP2D6MEN1KMT2A
SCHEMBL6188797 0.68 CYP2D6 (0.55) KCNH2CYP2D6MEN1KMT2ARAB9A
SCHEMBL4500756 0.67 ROCK2 (0.58) ROCK2ROCK1CCR2MEN1KMT2A
SCHEMBL5222045 0.67 CYP2D6 (0.54) CYP2D6MEN1KMT2A
SCHEMBL5226751 0.67 CYP2D6 (0.54) KCNH2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
EP-1578737-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2005-09-28 EP disclosed
WO-2004063180-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. (US) 2004-07-29 WO disclosed